Pharma StrategyNovo Nordisk Shuts Internal Cell Therapy Unit, Licenses Parkinson's Asset to AI Platform as Stock Gains 24.9%Via News Editorial Team•Jul 23, 2026
Corporate StrategyNovo Nordisk Outsources Parkinson's R&D to AI Partner as Big Pharma Drops Vertical IntegrationVia News Editorial Team•Jun 9, 2026
Corporate StrategyNovo Nordisk Licenses Cell Therapy to AI Spinout as Big Pharma Rewrites Its R&D PlaybookVia News Editorial Team•Jun 1, 2026
Pharma StrategyNovo Nordisk's 24.9% Rally Validates AI Licensing Over Internal Cell TherapyVia News Editorial Team•May 31, 2026
Corporate StrategyNovo Nordisk Closes Internal Cell Therapy Unit, Licenses Program to AI-Native Cellular IntelligenceVia News Editorial Team•May 21, 2026
Corporate Strategy & Business TransformationNovo Nordisk's 25% Stock Surge Validates Pharma's Pivot to AI Platform OutsourcingVia News Editorial Team•May 18, 2026
Pharma FinanceNovo Nordisk Licenses Parkinson's Program and Exits Cell Therapy as AI Reshapes Pharma R&DVia News Editorial Team•May 16, 2026
Pharma & HealthcareNovo Nordisk's 24.9% Stock Surge Validates Pharma's Pivot From Internal R&D to AI PartnershipsVia News Editorial Team•May 13, 2026